Dr Ruchi Gupta shares key updates including a new anaphylaxis definition, treatment advances, and emerging biologics for CSU.

Dr Gupta attended the 2025 AAAAI/WAO meeting in San Diego, highlighting new insights into anaphylaxis, angioedema, and urticaria. A key highlight was the consensus statement refining the ...

Omalizumab is superior to oral immunotherapy (OIT) for multifood allergy, and most patients include dietary consumption (DC) ...

an antibody therapy targeting c-Kit to treat mast cell-driven diseases like chronic spontaneous urticaria (CSU) and asthma, at the AAAAI 2025 Annual Meeting in San Diego. The new data, from a ...

Inc. (SPRY), a biopharmaceutical company focused on allergic reaction therapies, announced on Tuesday its participation in the 2025 American Academy of Allergy, Asthma, and Immunology or AAAAI ...

Asthma & Immunology annual meeting (AAAAI 2025). LP-003 demonstrated superior improvement compared to Omalizumab in mean change of UAS7 (urticaria activity score 7) from baseline and percentage ...